Entacapone adjunctive therapy clear choice in Parkinson's disease

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.297, 2001-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Entacapone in the management of Parkinson’s disease

By Waters Cheryl Henchcliffe Claire

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 957-963

Informa Healthcare

Access to resources Recommend Favorite

Entacapone: A Review of its Use in Parkinson's Disease

By Holm K.J. Spencer C.M.

Drugs, Vol. 58, Iss. 1, 1999-07 ,pp. : 159-177

Adis International

Access to resources Recommend Favorite

The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinson's Disease: A Retrospective Claims-Based Analysis

By Delea Thomas E.

CNS Drugs, Vol. 25, Iss. 1, 2011-01 ,pp. : 53-66

Adis International

Access to resources Recommend Favorite

Levodopa/carbidopa/entacapone: Pisa syndrome (first report with entacapone) in a patient with Parkinson's disease: case report

Reactions Weekly, Vol. 1, Iss. 1239, 2009-01 ,pp. : 20-21

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Treatment of Parkinson's Disease with Entacapone in the United States

By Palmer C.S.

PharmacoEconomics, Vol. 20, Iss. 9, 2002-09 ,pp. : 617-628

Adis International

Access to resources Recommend Favorite